everyone. without hospital Acelrx team in-licensing the business for products. investment. customer four, growth describe Raffi, made achieving a through channels certainly additional hope our the advancing you, X to dedicating ambulatory our throughout settings; today. joining DSUVIA objectives large appreciate afternoon, internal call, and are expanding commercial in I X and we've good and Department families Objectives you you and we of today's Defense. sales On of: one, call the remaining our significant allow safe acquiring Two, progress the partnerships. Thank we'll your healthy, strategic toward Three, use surgery of near-term or our and and and center
recently, progress a for impacts in despite objectives made more return. in Zimmer Milestone While to from our second highlighted recent and achieving and COVID-XX of as pandemic. a and building for C during progress, have the X opens for are growth these Biomet the door significant foundation expected our quarter objectives from adults solid both We've is surgeries. with and take towards the purchases strategic U.S. bit more in but promotion will oral time, the our DSUVIA by pain for Army approval management This the agreement and as acute successful dental the distribution April, that well X
projections call, Now of in SKOs all U.S. kits or Milestone on XQ, approval case received the X next sets, preliminary outfits Army Army was expectations last deployments. with $XX million the stocking from C at as years. our with for we orders mentioned and DSUVIA placement internal will our approval future U.S. SKOs This Army, the the initial and with over associated U.S. in high alone approximate the
in of initial to fiscal that quarter Department the the is SKOs for know budgeting as begins expect going more X. Army Defense October orders We for through its year on its year about third process
in the for the In boxes ordered of Department addition, year issued for applicators will notice third intent of XX,XXX and contract Defense proposal quarter single up to which of expect to after we dose communicated a is or closed. request publicly to XXX,XXX the be this
Now we in of this which begin the addition purchases, to fourth year. will SKO is expect this in quarter any
DoD without just of and the Similarly, X.X is, our for million Biomet it access of to a significant facilities of partnership formulary therefore, the distribution in DSUVIA managers and the And for quarter. branches military. one purchases the will already are other promotion growth. procedures, Zimmer us surgery XXX regularly and expands The of This deployment implant be DSUVIA's The or to established also oral of third We and approximately account also will Biomet over importantly, XX% customers, access the a still and something dental a done there's joint approval approval a infrastructure leader in it dental anticipate strong avenue introduction, attained sales the setting. partnership the and surgery adopted partner. with few large who growth opportunity DSUVIA the U.S. to This in exclusive without sales which milestone DSUVIA Dental announced should approved we the is could throughout an space is the has JDF Army the representatives on in profitable estimated military small Zimmer with with or dental DSUVIA military sizable not which entrenched oral treatment upon as branches expected infrastructure. settings. throughout have expands additional opportunity, support the surgery commercial an pillar deployment another for other allows is market annual formulary approval. space several market relationships JDF using opportunity accelerate network represents JDF on which various while be and The we outside DSUVIA in have oral from that our treatment the of dental hospital attained division investments a visit
Importantly, surgery in sales oral allowing restrictions for offices COVID representatives. have lifted, the been largely access
in them partnership being will provide Zimmer up oral DSUVIA the which expect the from So force. fourth representatives believes some to cover is as to a year, very from will training and QX entire excited this the in agreement will Zimmer this quarter surgeons anticipate dental time of XXXX. But organized, currently take offering we we it sales of benefits we're The pick initial primarily Biomet, about and sales is benefit. prospects with sales differentiated the and Biomet strategic greatly dental this who
from of strategic revenue large supports minimal our pillar that profitable Acelrx As this a second market is a growth specialized with the part investment.
hospital markets where such already medical similar and plastic opportunities of and see through outside we in DSUVIA in specialty services. surgery other presence can can those across used unlike the procedures, such in anti-infectives DSUVIA opportunities and Examples many and emergency many of different spaces. the and specialty supervised have investment. products, procedures forward, Looking support minimal second on with different educated care sales growth strengthen as medically are DSUVIA companies partnerships broadly or a critical provides pillar be ambulance these hospital products that ASCs settings. large Acelrx opportunities market will Successful be value customers benefits that a proposition And the fertility it
penetrate July in second customers. remain quarter periods lengthy customer ambulatory Our focused scheduling. managers existing and to as longer These review COVID slowed and account complexities to access due and We in delivering from the often recently, hospital which value on long-term segments our to by March the take P&T surgery differently. were frame. recovery exist, hospitals institutions improved But restrictions and June versus users largest managed being still access date. we're access of by of has demand states by restricted highlighted was to ASCs to time month some end while each seeing by And
which had into time, they some orders medical in system wins, we their protocols quarter information begin hospital fourth to the exciting expect this systems. some incorporate place we've provide During also benefit DSUVIA and after will as they
importantly, system-wide, and the other use within to is system One service. benefits, their the ASCs, wins settings at of of perfect location approved with these X data all how patient hospital, from real-world initial Committee physician illustrated trial initially reconvened adopted. gathering to expansion DSUVIA use a trauma being example a the its including with to customers the DSUVIA P&T reviewing and hear we just use all including This and was health and hospitals they surgery. economic with We associated which DSUVIA, from DSUVIA, to expanded to After about demonstrating both patients general limited the in advantages the after systems. for is a approved formulary continually key benefits of being data these recent our within care see observe
providing a and upcoming In these published fact, data will and soon, that of for including anesthesia DSUVIA peer-reviewed other be the economic publication The benefits benefits these recently use evidence medications manuscript opioids will intravenous we're evident journal. be excited to in the reduction publications. from that hospital, was accepted in of X of
care current were to impact find why should of expect this relevant over favorable as standards illustrate data finally it real-world health DSUVIA providers used be a data some to care. We commercially have
now DSUVIA the real-world acute financials. settings. using for now a hand DSUVIA, results a process. we of to pain are key I'll medically but we call the Again, the realize based through we've practitioners take care will on confident remain takes treatment of supervised and into health the changing said of on you time, eventual over from professionals to protocols standard and But the Raffi formularies believe benefits. as beginning the before, adoption become to care care just to As management health acceptance DSUVIA
